Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
enzyme replacement therapy |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
A16AB15
|
| gptkbp:brand |
gptkb:Strensiq
|
| gptkbp:CASNumber |
928005-87-0
|
| gptkbp:developer |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:drugClass |
gptkb:enzyme
|
| https://www.w3.org/2000/01/rdf-schema#label |
asfotase alfa
|
| gptkbp:indication |
juvenile-onset hypophosphatasia
perinatal/infantile-onset hypophosphatasia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:protein
|
| gptkbp:mechanismOfAction |
replaces tissue-nonspecific alkaline phosphatase
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
injection site reaction
hypersensitivity lipodystrophy ectopic calcification |
| gptkbp:UNII |
6U8Z330A6M
|
| gptkbp:usedFor |
treatment of hypophosphatasia
|
| gptkbp:bfsParent |
gptkb:Strensiq
gptkb:hypophosphatasia |
| gptkbp:bfsLayer |
7
|